ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan Sells 3,477 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Brendan Teehan sold 3,477 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $58,900.38. Following the sale, the chief operating officer now directly owns 42,133 shares in the company, valued at $713,733.02. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Brendan Teehan also recently made the following trade(s):

• On Monday, April 8th, Brendan Teehan sold 2,568 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.87, for a total transaction of $45,890.16.
• On Wednesday, March 27th, Brendan Teehan sold 5,140 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.90, for a total transaction of $92,006.00.
• On Monday, February 26th, Brendan Teehan sold 624 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $24.67, for a total value of $15,394.08.

ACADIA Pharmaceuticals Trading Down 0.2 %

ACADIA Pharmaceuticals stock opened at $17.05 on Friday. The firm has a 50 day moving average of $19.15 and a 200 day moving average of $23.33. The firm has a market capitalization of $2.82 billion, a price-to-earnings ratio of -44.87 and a beta of 0.42. ACADIA Pharmaceuticals Inc. has a 12-month low of $16.16 and a 12-month high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.04). The firm had revenue of $231.04 million during the quarter, compared to analysts’ expectations of $223.79 million. ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The company’s revenue was up 69.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) earnings per share. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current year.

Analyst Ratings Changes

ACAD has been the topic of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $42.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Royal Bank of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 9th. Robert W. Baird assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, January 30th. They set an “outperform” rating and a $40.00 target price on the stock. Finally, TheStreet upgraded shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.13.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP grew its holdings in ACADIA Pharmaceuticals by 18.3% during the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock valued at $241,255,000 after buying an additional 1,793,288 shares in the last quarter. Fred Alger Management LLC grew its holdings in ACADIA Pharmaceuticals by 38.7% during the 3rd quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company’s stock valued at $64,789,000 after buying an additional 867,818 shares in the last quarter. First Trust Advisors LP grew its holdings in ACADIA Pharmaceuticals by 9.1% during the 4th quarter. First Trust Advisors LP now owns 1,777,307 shares of the biopharmaceutical company’s stock valued at $55,647,000 after buying an additional 148,526 shares in the last quarter. Emerald Advisers LLC grew its holdings in ACADIA Pharmaceuticals by 4.0% during the 3rd quarter. Emerald Advisers LLC now owns 1,681,052 shares of the biopharmaceutical company’s stock valued at $35,033,000 after buying an additional 64,100 shares in the last quarter. Finally, Norges Bank bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at approximately $45,187,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.